Substantial improvement in a Meige's syndrome patient with levetiracetam treatment

Movement Disorders

Volumn 19, Issue 12, 2004, Pages 1518-1521

  Zesiewicz, Theresa A ^a,b,e   Louis, Elan D ^c   Sullivan, Kelly L ^a,b   Menkin, Martin ^d   Dunne, Peter B ^b   Hauser, Robert A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d FLORIDA HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

Cervical dystonia; Keppra; Levetiracetam; Meige's syndrome

Indexed keywords

ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; CLORAZEPATE; ETIRACETAM; GABAPENTIN;

ADULT; ARTICLE; BLEPHAROSPASM; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; DYSTONIA; FEMALE; HUMAN; IDIOPATHIC DISEASE; MEIGE DISEASE; MYOMECTOMY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; VISUAL SYSTEM EXAMINATION;

ANTICONVULSANTS; FEMALE; HUMANS; MEIGE SYNDROME; MIDDLE AGED; PIRACETAM; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 12144268710     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20233     Document Type: Article

References (38)

1. Meige H. Les convulsions de la face, une forme clinique de convulsion faciale, bilaterale et mediane. Rev Neurol 1910;20: 437-443.
2. Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Breughel syndrome). J Neurol Neurosurg Psychiatry 1976;39: 1204-1209.
3. Tubiana R. Musician's focal dystonia. Hand Clin 2003;19:303-308, vii.
4. Brashear A. The botulinum toxins in the treatment of cervical dystonia. Semin Neurol 2001;21:85-90.
5. Faulstich ME, Carnrike CLM, Williamson DA. Blepharospasm and Meige syndrome: a review of diagnostic, aetiological and treatment approaches. J Psychosomatic Res 1985;29:89-94.
6. Jacome DE, Yanez GF. Spastic dysphonia and Meige disease. Neurology 1980;30:349.
7. Micheli F. Responses to lisuride in Meige's disease and chorea. Neurology 1986;36:445.
8. Karp BI, Goldstein SR, Chen R, et al. An open trial of clozapine for dystonia. Mov Disord 1999;14:652-657.
9. Gollomp SM, Fahn S, Burke RE, et al. Therapeutic trials in Meige syndrome. Adv Neurol 1983;37:207-213.
10. Tanner CM, Glantz RH, Klawans HL. Meige syndrome (blepharospasm/oromandibular dystonia syndrome): analysis of clinical pharmacology in 12 patients. Neurology 1981;31:78.
11. Fisher CM. Pharmacology of cranial dystonia. Neurology 1983; 33:1101.
12. Marsden CD, Lang AE, Sheehy MD. Pharmacology of cranial dystonia. Neurology 1983;33:1100-1101.
13. Lang AE, Sheehy MP, Marsden CD. Anticholinergics in adult-onset focal dystonia. Can J Neurol Sci 1982;9:313-319.
14. Nutt JG, Hammerstad JP, de Gramo P, Carter J. Cranial dystonia: double-blind crossover study of anticholinergics. Neurology 1984; 34:215-217.
15. Engstrom PF, Arnoult JB, Mazow ML, et al. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 19987;94:971-975.
16. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37:616-623.
17. Fahn S, List T, Moskowitz C, et al. Double-blind controlled study of botulinum toxin for blepharospasm. Neurology 1975;35(Suppl. 1):271.
18. Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 2000;391:251-254.
19. Fahn S, Marsden CD, Calne DB. Classification and investigation of dystonia. In: Marsden CD, Fahn S, editors. Movement disorders 2. London: Butterworth and Co; 1987. p 332-358.
20. Casey DE. Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurology 1980;30:690-695.
21. Walsh FB, Hoyt WF. Clinical-neuro-ophthalmology. 3rd ed. Baltimore: Williams and Wilkins; 1969. p 3334.
22. Freuh BR, Callahan A, Dortzbach RK, et al. The effects of differential section of the VIIth nerve on patients with intractable blepharospasm. Trans Am Acad Ophthalmol Otolaryngol 1976;81: OP595-OP602.
23. Bates AK, Halliday BL, Bailey CS, et al. Surgical management of essential blepharospasm. Br J Ophthlamol 1991;75:487-490.
24. McCord CD, Coles WH, Shore W, et al. Treatment of essential blepharospasm. I. Comparison of facial nerve avulsion and eyebrow-eyelid muscle stripping procedure. Arch Ophthalmol 1984; 102:266.
25. Gillum WN, Anderson RL. Blepharospasm surgery. An anatomical approach. Arch Ophthalmol 1981;99:1056-1062.
26. Patel BCK, Anderson RL. Diagnosis and management of essential blepharospasm. Ophthalmic Pract 1993;11:293-302.
27. Freuh BR, Musch DC, Bersani TA. Effects of eyelid protractor excision for the treatment of benign essential blepharospasm. Am J Ophthalmol 1992;113:681-686.
28. Bettez M, Lavertua P. Periorbital myectomy for essential blepharospasm. J Otolarynol 1986;15:306-309.
29. Jones TW Jr, Waller RR, Samples JR. Myectomy for essential blepharospasm. Mayo Clin Proc 1985;60:663-666.
30. Capelle HH, Weigel R, Krauss JK. Bilateral pallidal stimulation for blepharospasm-oromandibular dystonia (Meige syndrome). Neurology 2003;60:2017-2018.
31. Castelbuono A, Miller NR. Spontaneous remission in patients with essential blepharospasm and Meige syndrome. Am J Ophthalmol 1998;126:432-435.
32. Mauriello JA, Aljian J. Natural history of treatment of facial dyskinesias with botulinum toxin: a study of 50 consecutive patients over seven years. Br J Ophthalmol 1991;75:737-739.
33. Mauriello JA, Dhillon S, Leone T, et al. Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years. Br J Ophthalmol 1996;80:1073-1076.
34. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
35. Shorvon SD, Lowenthal A, Janz D, et al. Multi-center double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186.
36. Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multi-institution study in Japan. Mov Disord 1996;11:691-700.
37. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001;57:1112-1114.
38. Piperidou C, Maltezos E, Kafalis G, et al. Piracetam for choreoathetosis. Lancet 1988;2:906.